Pembrolizumab plus axitinib continued to demonstrate superior efficacy compared with sunitinib monotherapy in patients with previously untreated advanced clear-cell RCC with a median follow-up of 42 months.
With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.
With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.
Exploratory analyses of the CheckMate 9ER trial suggested PFS benefit with nivolumab + cabozantinib vs sunitinib across assessed subgroups defined by baseline disease characteristics.
In patients with metastatic castration-sensitive prostate cancer, the addition of abiraterone to standard of care, ADT with or without docetaxel, prolonged median radiographic PFS by more than 2 years.
Updated safety analysis of EORTC GUCG 1333/PEACE-3 confirms that risk of fractures was well controlled in both treatment arms when patients with mCRPC received BPAs.
In this phase III trial, addition of 177Lu-PSMA-617 to standard of care in men with previously treated PSMA-positive mCRPC prolonged OS and radiographic PFS vs standard of care alone.
Results of the first interim analysis for this randomized, double-blind phase III trial demonstrated significantly improved DFS with adjuvant pembrolizumab in patients with clear-cell RCC following nephrectomy.